| Urogenital Neoplasms |
| Completed | 2 | 63 | RoW | Dendritic Cells DCVAC/PCa, Leuprolide acetate, Lupron, Goserelin Acetate, Zoladex | SOTIO a.s., Ascend Biopharmaceuticals Ltd | Basal Cell Carcinoma, Basal Cell Nevus Syndrome (BCNS) | 12/15 | 06/16 | | |
NCT00636259: Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer |
|
|
| No Longer Available | N/A | | US | Bicalutamide (Casodex) | AstraZeneca | Adenocarcinoma of the Prostate | | | | |
NCT00655252 / 2007-005460-28: Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy |
|
|
| No Longer Available | N/A | | US, Canada, Europe, RoW | Everolimus | Novartis Pharmaceuticals | Metastatic Renal Cell Cancer | | | | |
|
|
|
NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment |
|
|
| No Longer Available | N/A | | Canada, RoW | Axitinib, AG-013736 | Pfizer | Renal Cell Carcinoma | 03/14 | 03/14 | | |
NCT01516762: Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases |
|
|
| No Longer Available | N/A | | US | Radium-223 dichloride (BAY88-8223) | Bayer | Prostatic Neoplasms | | | | |
|
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT01834209: A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| No Longer Available | N/A | | RoW | Abiraterone acetate, Prednisone or prednisolone | Janssen Research & Development, LLC | Prostate Neoplasms | | | | |
| Enrolling by invitation | N/A | 10000 | Europe | Screening for cervical cancer | Tampere University, FinnMedi Oy, GlaxoSmithKline | Uterine Cervical Cancer | 12/24 | 12/24 | | |